• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes.

作者信息

Camelo Ricardo Mesquita, de Medeiros Tenille Capuxú, de Albuquerque Daniela Gonçalves Braz, Álvares-Teodoro Juliana

机构信息

Faculdade de Medicina da Universidade Federal de Minas Gerais, 1020/101 Padre Eustáquio, Belo Horizonte, MG, Brazil.

Centro de Hematologia e Hemoterapia do Rio Grande do Norte (HEMONORTE), Natal, RN, Brazil.

出版信息

Hematol Transfus Cell Ther. 2023 Jan-Mar;45(1):98-101. doi: 10.1016/j.htct.2021.02.010. Epub 2021 May 7.

DOI:10.1016/j.htct.2021.02.010
PMID:34303653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9938495/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c30/9938495/9d59aa0536a9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c30/9938495/23fb062f09f8/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c30/9938495/9d59aa0536a9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c30/9938495/23fb062f09f8/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c30/9938495/9d59aa0536a9/gr2.jpg

相似文献

1
Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes.对一名重度甲型血友病且产生抑制剂、免疫耐受诱导失败的男性进行12个月的emicizumab预防治疗：疗效、经济性和安全性结果。
Hematol Transfus Cell Ther. 2023 Jan-Mar;45(1):98-101. doi: 10.1016/j.htct.2021.02.010. Epub 2021 May 7.
2
Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.接受emicizumab预防出血事件的血友病 A 患者延迟抑制剂开发的经济影响模型。
J Med Econ. 2019 Dec;22(12):1328-1337. doi: 10.1080/13696998.2019.1669614. Epub 2019 Oct 7.
3
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors.依库珠单抗预防治疗血友病 A 患者抑制物的成本效果及预算影响。
Thromb Haemost. 2020 Feb;120(2):216-228. doi: 10.1055/s-0039-3401822. Epub 2019 Dec 30.
4
Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations.A型血友病治疗中艾美赛珠单抗的聚焦：患者选择及特殊考量
J Blood Med. 2019 Jul 2;10:171-181. doi: 10.2147/JBM.S175952. eCollection 2019.
5
Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors.新血友病时代的关键问题：血友病A伴抑制剂患者中FVIII与艾美赛珠单抗联合使用的最新情况
Expert Rev Hematol. 2021 Feb;14(2):143-148. doi: 10.1080/17474086.2021.1875817. Epub 2021 Jan 27.
6
Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru.秘鲁重度 A 型血友病患者使用艾美赛珠单抗与旁路制剂预防的成本效果研究。
Medwave. 2022 Mar 15;22(2):e8703. doi: 10.5867/medwave.2022.02.002118.
7
Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.接受emicizumab预防治疗的血友病 A 伴抑制物患儿的免疫耐受诱导。
Haemophilia. 2019 Sep;25(5):789-796. doi: 10.1111/hae.13819. Epub 2019 Aug 2.
8
Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.使用体外模拟模型预测接受依库珠单抗预防和免疫耐受诱导治疗的血友病 A 患者抑制物的凝血潜能。
Int J Hematol. 2021 Jun;113(6):789-796. doi: 10.1007/s12185-021-03108-8. Epub 2021 Feb 26.
9
Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab.真实世界病例系列研究及目前文献综述：婴幼儿重型 A 型血友病伴抑制物患者接受艾美赛珠单抗预防治疗的情况。
Pediatr Blood Cancer. 2021 May;68(5):e28942. doi: 10.1002/pbc.28942. Epub 2021 Feb 8.
10
Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A.艾美赛珠单抗预防治疗 A 型血友病患者的安全性评估。
Expert Opin Drug Saf. 2021 Apr;20(4):387-396. doi: 10.1080/14740338.2021.1893303. Epub 2021 Feb 27.

本文引用的文献

1
WFH Guidelines for the Management of Hemophilia, 3rd edition.《血友病管理的居家指南》第三版
Haemophilia. 2020 Aug;26 Suppl 6:1-158. doi: 10.1111/hae.14046. Epub 2020 Aug 3.
2
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors.依库珠单抗预防治疗血友病 A 患者抑制物的成本效果及预算影响。
Thromb Haemost. 2020 Feb;120(2):216-228. doi: 10.1055/s-0039-3401822. Epub 2019 Dec 30.
3
ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII.
一名接受艾美赛珠单抗和重组活化凝血因子 VII 治疗的甲型血友病患者发生 ST 段抬高型心肌梗死（STEMI）和肺栓塞
Haemophilia. 2020 Jan;26(1):e5-e8. doi: 10.1111/hae.13871. Epub 2019 Nov 6.
4
Emicizumab and thrombosis: The story so far.依美珠单抗与血栓形成：迄今为止的情况。
J Thromb Haemost. 2019 Aug;17(8):1269-1272. doi: 10.1111/jth.14556.
5
Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.rFVIIa 与emicizumab 给药用于伴抑制物的先天性血友病 A 的安全性分析：来自 HAVEN 临床项目的经验。
J Thromb Haemost. 2019 Sep;17(9):1470-1477. doi: 10.1111/jth.14491. Epub 2019 Jun 17.
6
Evaluating the safety of emicizumab in patients with hemophilia A.评估艾美赛珠单抗在血友病 A 患者中的安全性。
Expert Opin Drug Saf. 2018 Dec;17(12):1233-1237. doi: 10.1080/14740338.2019.1551356. Epub 2018 Nov 28.
7
Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.依库珠单抗，一种人源化的双特异性抗体，靶向凝血因子 IXa 和 X，同时具有因子 VIIIa 辅因子活性。
Int J Hematol. 2020 Jan;111(1):20-30. doi: 10.1007/s12185-018-2545-9. Epub 2018 Oct 22.
8
Immune tolerance induction: What have we learned over time?免疫耐受诱导：随着时间的推移，我们学到了什么？
Haemophilia. 2018 Apr;24 Suppl 3:3-14. doi: 10.1111/hae.13445.
9
Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.血友病和抑制剂患者中旁路制剂的使用与血栓栓塞事件风险。
Thromb Haemost. 2017 Dec;117(12):2267-2273. doi: 10.1160/TH17-05-0365. Epub 2017 Dec 6.
10
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.依库珠单抗预防伴抑制物的血友病 A。
N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10.